TFPI

TFPI

TFPI Informations sur la molécule

Molecule Name
Tissue factor pathway inhibitor
Alias de la molécule
TFPI,LACI,TFPI1,EPI,TFI
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés2
Phase de R&D la plus avancéeApproved
Alias de la cible
TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Contexte de la molécule
Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI Liste de produits

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
TFPI
Human TFPI Protein, His Tag (active enzyme)
Human
HEK293
SDS-PAGE
Enzyme

$320.00

50ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co Ltd
Hemophilia A; Hemophilia B
Details
MG-1113MG-1113; MG-1113APhase 1 ClinicalGC Biopharma Corp
Hemophilia A
Details
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hemophilia A; Hemophilia B
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
ConcizumabAnti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17
Hemophilia A; Hemophilia B; Hemorrhage
Details
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZI, 友瑞宁United StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11
Hemophilia A; Hemophilia B; Hemorrhage
Details
Customer Reviews